GMED

Business Context and Reporting Period

Company: Globus Medical, Inc. (GMED)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Globus Medical is a medical device company focused on musculoskeletal solutions, including implants, robotic guidance systems, and neuromonitoring services. The company operates globally with a primary focus on the U.S. market.

Key Financial Metrics

Note: Q2 2025 Net Income included a non-recurring bargain purchase gain of $110.6 million related to the Nevro Merger.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 5.9% in Q2 2026 and 15.3% for the six months ended June 30, 2026, compared to the prior year. Growth was driven by Musculoskeletal Solutions (spine implants and neuromonitoring) and Nevro sales, particularly in international markets (up 18.0% in Q2).
• Operating Profitability: Operating income surged 139.7% in Q2 2026 ($182.4M vs. $76.1M) and 92.3% for the six-month period. This improvement is largely due to a significant reduction in acquisition-related costs and restructuring expenses compared to the prior year, which included heavy integration costs for the Nevro Merger.
• Net Income Volatility: While operating income increased, Net Income for Q2 2026 decreased 25.3% compared to Q2 2025. This decline is primarily attributable to the absence of the $110.6 million non-taxable bargain purchase gain recorded in Q2 2025.
• Cost Management: Cost of sales as a percentage of net sales improved to 30.6% in Q2 2026 from 33.4% in Q2 2025, aided by the absence of inventory step-up amortization from the prior year.

Guidance, Outlook, and Risks

• Management Commentary: Management highlighted strong demand for spine implantable devices and neuromonitoring services. The company continues to invest in surgical sets and sales force expansion in the U.S. and international markets.
• Capital Allocation: The company repurchased 1.6 million shares for $136.1 million in Q2 2026. As of June 30, 2026, $253.9 million remains available under the $500 million share repurchase program authorized in May 2025.
• Liquidity: The company maintains a strong liquidity position with $507.7 million in cash and cash equivalents and $332.8 million in marketable securities. There are no outstanding borrowings under the $400 million revolving credit facility.
• Legal Contingencies:
  • Pimenta Litigation: A jury verdict in November 2025 awarded $28.7 million in damages against NuVasive (a Globus subsidiary). Globus recorded a $43.1 million liability (including interest/costs) in 2025 and has filed an appeal. No additional charges were recorded in Q2 2026.
  • Moskowitz Litigation: An appeal is pending following a defense verdict in 2023. No liability is currently recorded.
  • 4WEB Litigation: Ongoing patent infringement suit regarding Modulus products; outcome and potential loss are currently indeterminable.
• Tax Rate: The effective tax rate for Q2 2026 was 20.1%, an increase from the prior year's benefit of (7.8%), driven by the absence of the non-taxable bargain purchase gain and a one-time state valuation allowance release in the prior period.

Investor Verification Checklist

• Recurring Profitability: Verify the sustainability of operating margins excluding the one-time bargain purchase gain from the prior year.
• Legal Exposure: Monitor the status of the Pimenta litigation appeal and potential outcomes of the 4WEB and Moskowitz cases.
• Acquisition Integration: Assess the progress of the Nevro Merger integration and the impact of remaining contingent consideration liabilities ($105.4 million).
• Share Repurchases: Track the utilization of the remaining $253.9 million repurchase authorization and its impact on earnings per share.
• International Growth: Validate the drivers of the 18% international sales growth and exposure to foreign currency fluctuations.